Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 562-571

  Satoh, Takefumi ^a   Teh, Bin S ^a   Timme, Terry L ^a   Mai, Wei Yuan ^a   Gdor, Yehoshua ^a   Kusaka, Nobuyuki ^a   Fujita, Tetsuo ^a   Pramudji, Christina K ^a   Vlachaki, Maria T ^a   Ayala, Gustavo ^a   Wheeler, Thomas ^a   Amato, Robert ^a   Miles, Brian J ^a   Kadmon, Dov ^a   Butler, E Brian ^a   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytotoxic gene therapy; HSV tk GCV gene therapy; IMRT; Prostate cancer; Radio gene therapy

Indexed keywords

ANTIBODIES; BLOOD; DISEASES; ENZYMES; GENES; IMMUNOLOGY; RADIOTHERAPY; TOXICITY; TUMORS;

CELL ACTIVATION; GENE THERAPY;

ONCOLOGY;

ADENOVIRUS VECTOR; ANTIBODY; CD8 ANTIGEN; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; VALACICLOVIR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIBODY LABELING; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CELL SELECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; GENE THERAPY; HEALTH PROGRAM; HEPARINIZATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INJECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ACYCLOVIR; ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; AVIAN SARCOMA VIRUSES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; GANCICLOVIR; GENE THERAPY; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PRODRUGS; PROSTATECTOMY; PROSTATIC NEOPLASMS; THYMIDINE KINASE; VALINE;

EID: 2442512179     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.020     Document Type: Article

References (41)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
2. Brawley O.W., Giovannucci E., Kramer B.S. Epidemiology of prostate cancer. Vogelzang N.J., Scardino P.T., Shipley W.U., et al. Comprehensive textbook of genitourinary oncology. 2nd ed:2000;533-544 Lippincott Williams & Wilkins, Philadelphia
3. Freeman S.M., Abboud C.N., Whartenby K.A., et al. The "bystander effect:" Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283
4. Eastham J.A., Chen S.H., Sehgal I., et al. Prostate cancer gene therapy Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 7:1996;515-523
5. Hall S.J., Mutchnik S.E., Chen S.H., et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer. 70:1997;183-187
6. Hall S.J., Mutchnik S.E., Yang G., et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 6:1999;54-63
7. Thompson T.C., Timme T.L., Ebara S., et al. In situ gene therapy for prostate cancer Immunomodulatory approaches. Expert Opin Biol Ther. 1:2001;481-495
8. Herman J.R., Adler H.L., Aguilar-Cordova E., et al. In situ gene therapy for adenocarcinoma of the prostate A phase I clinical trial. Hum Gene Ther. 10:1999;1239-1249
9. Miles B.J., Shalev M., Aguilar-Cordova E., et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 12:2001;1955-1967
10. Ayala G., Wheeler T.M., Shalev M., et al. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 31:2000;866-870
11. Vlachaki M.T., Chhikara M., Aguilar L., et al. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys. 51:2001;1008-1017
12. Chhikara M., Huang H., Vlachaki M.T., et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther. 3:2001;536-542
13. Teh B.S., Aguilar-Cordova E., Kernen K., et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - A preliminary report. Int J Radiat Oncol Biol Phys. 51:2001;605-613
14. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 90:1998;766-771
15. Chen S.H., Shine H.D., Goodman J.C., et al. Gene therapy for brain tumors Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A. 91:1994;3054-3057
16. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization Acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys. 49:2001;705-712
17. Teh B.S., Mai W.Y., Grant W.H. 3rd, et al. Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control. Cancer Invest. 20:2002;437-451
18. Timme T.L., Hall S.J., Barrios R., et al. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther. 5:1998;74-82
19. Shalev M., Kadmon D., Teh B.S., et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 163:2000;1747-1750
20. Moolten F.L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:1994;279-287
21. Colombo B.M., Benedetti S., Ottolenghi S., et al. The "bystander effect:" Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther. 6:1995;763-772
22. Hamel W., Magnelli L., Chiarugi V.P., et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56:1996;2697-2702
23. Barba D., Hardin J., Sadelain M., et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A. 91:1994;4348-4352
24. Vile R.G., Nelson J.A., Castleden S., et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:1994;6228-6234
25. Hoppe R.T., Fuks Z.Y., Strober S., et al. The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation. Cancer. 40:1977;2071-2078
26. Order S.E. The effects of therapeutic irradiation on lymphocytes and immunity. Cancer. 39:1977;737-743
27. Heier H.E. The influence of therapeutic irradiation of blood and peripheral lymph lymphocytes. Lymphology. 11:1978;238-242
28. Job G., Pfreundschuh M., Bauer M., et al. The influence of radiation therapy on T-lymphocyte subpopulations defined by monoclonal antibodies. Int J Radiat Oncol Biol Phys. 10:1984;2077-2081
29. Yang S.J., Rafla S., Youssef E., et al. Changes in T-cell subsets after radiation therapy. Radiology. 168:1988;537-540
30. De Ruysscher D, Waer M, Vandeputte M, et al. Changes of lymphocyte subsets after local irradiation for early stage breast cancer and seminoma testis: Long-term increase of activated (HLA-DR+) T cells and decrease of "naive" (CD4-CD45R) T lymphocytes. Eur J Cancer 1992;28A:1729-1734
31. Belka C., Ottinger H., Kreuzfelder E., et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol. 50:1999;199-204
32. Stevens C.W., Zeng M., Cerniglia G.J. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther. 7:1996;1727-1734
33. Tang D.C., Jennelle R.S., Shi Z., et al. Overexpression of adenovirus-encoded transgenes from the cytomegalovirus immediate early promoter in irradiated tumor cells. Hum Gene Ther. 8:1997;2117-2124
34. Zeng M., Cerniglia G.J., Eck S.L., et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther. 8:1997;1025-1032
35. Jain P.T., Gewirtz D.A. Sustained enhancement of liposome-mediated gene delivery and gene expression in human breast tumour cells by ionizing radiation. Int J Radiat Biol. 75:1999;217-223
36. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 10:1998;588-594
37. Kalams S.A., Walker B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 188:1998;2199-2204
38. Wang R.F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22:2001;269-276
39. Hung K., Hayashi R., Lafond-Walker A., et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 188:1998;2357-2368
40. Greenberg P.D. Adoptive T cell therapy of tumors Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 49:1991;281-355
41. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327